Search this website. You can use fund codes to locate specific funds

Risk

  • June 2, 2021
    Novartis case study
    Pauline Lecoursonnois
    Novartis has increased its board gender diversity, appointed its first new auditor since 1940 and shown leadership on artificial intelligence.
  • April 22, 2021
    Tackling post-pandemic pharmaceutical challenges
    Katie Frame
    Why companies and investors need to step up to tackle pharmaceutical challenges in a post-pandemic world.
  • December 2, 2020
    Alphabet case study
    Christine Chow
    Alphabet has published a set of principles to promote the responsible use of AI, followed by white papers, case studies, fairness indicators, and ethical dashboards and tool suites for enterprises and developers that use its technologies for building their own AI systems.
  • August 28, 2020
    Antimicrobial resistance and the challenge for pharmaceutical companies
    Kimberley Lewis
    A lack of research and development into new antibiotic classes compounds the serious threat that antimicrobial resistance poses to public health.
  • March 24, 2020
    Supply chain risk, employees and the coronavirus
    Christine Chow
    The coronavirus pandemic is forcing governments around the globe to enact emergency legislation to contain the spread of COVID-19, with cities in lockdown, shops, theatres and restaurants closed, and office workers logging on at home. What can companies do to manage their way through this difficult period?
  • March 19, 2020
    The coronavirus and crisis management
    Christine Chow
    A public health crisis often leads to regulatory changes, as well as shifts in cultural expectations and human behaviour. What can companies do to mitigate the worst impacts of a major crisis? There are several areas for board members and company executives to consider.